Illumina (ILMN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

ILMN teams up with NVIDIA to advance technology platforms for the analysis and interpretation of multiomic data.

Claro Advisors LLC lessened its holdings in Illumina, Inc. (NASDAQ:ILMN – Free Report) by 17.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the ...

Illumina raises Q4 and FY24 revenue outlook, expects solid margins, with projected 2024 EPS between $4.12 and $4.14.

Illumina Inc (ILMN) stock saw a modest uptick, ending the day at $144.22 which represents a slight increase of $7.53 or 5.51% from the prior close of $136.69. The stock opened at $137 and touched a ...

In a report released on January 10, Conor McNamara from RBC Capital maintained a Buy rating on Illumina (ILMN – Research Report), with a price ...

Nvidia partners with industry leaders in life sciences to use AI for drug discovery, genomics research, and healthcare innovation. Read more here.

In a report released today, Tejas Savant from Morgan Stanley maintained a Hold rating on Illumina (ILMN – Research Report), with a price target ...

The deal values privately held Truveta at more than $1 billion, it said. Biotechnology company Regeneron pledged to put in ...

Study will generate a key reference data set with Illumina Protein Prep solution ...

The stock's fall snapped a four-day winning streak.

Stock analysts at Leerink Partnrs decreased their Q4 2025 earnings per share (EPS) estimates for Illumina in a note issued to ...